Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.11
-1.3%		$1.75
$0.94
▼
$46.50
$7.71M2.852.58 million shs30,390 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-3.45%-25.33%-76.17%-88.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.11
-1.3%		$1.75
$0.94
▼
$46.50
$7.71M2.852.58 million shs30,390 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-3.45%-25.33%-76.17%-88.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.50
Moderate Buy$67.505,953.81% Upside

Current Analyst Ratings Breakdown

Latest CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/18/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/11/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$620K12.55N/AN/A$9.14 per share0.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$46.90M-$10.32N/AN/AN/A-6,531.77%-210.99%-174.97%11/5/2026 (Estimated)

Latest CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$3.00-$1.46+$1.54-$1.46$0.13 million$0.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
1.81
1.52

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1006.98 million6.82 millionNo Data

Recent News About These Companies

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-completes-new-vector-smart-laboratory-installations-amid-rising-dengue-activity-in-florida-302874606.html
Co-Diagnostics Appoints New Principal Financial Officer
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/co-diagnostics-appoints-new-principal-financial-officer?utm_source=marketbeat.com&utm_medium=referral
Co-Diagnostics Adjourns Annual Meeting, Sets New Date
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/co-diagnostics-adjourns-annual-meeting-sets-new-date?utm_source=marketbeat.com&utm_medium=referral
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
September 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-launches-integrated-cloud-and-mobile-infrastructure-in-india-302868532.html
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-expands-vector-smart-customer-reach-with-first-international-installation-in-usaf-base-302865873.html
Co-Dx (CODX) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/co-dx-codx-q2-2026-235014355.html
Positive Report for Co-Diagnostics (CODX) from Maxim Group
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CODX/pressreleases/3927328/positive-report-for-co-diagnostics-codx-from-maxim-group/
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
August 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-participates-in-medical-devices-and-innovations-roundtable-media-event-302853820.html
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936453-co-diagnostics-inc-codx-q2-2026-earnings-call-transcript
Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4632962-co-diagnostics-outlines-fda-dual-510-k-and-clia-waiver-submission-as-cash-falls-to-3_6m
Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings
August 13, 2026  |  quiverquant.comQ
Co-Diagnostics Reports Second Quarter 2026 Financial Results
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-reports-second-quarter-2026-financial-results-302851294.html
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-submits-fda-510k-premarket-notification-for-upper-respiratory-point-of-care-test-302844796.html
Why Is Co-Diagnostics (NASDAQ:CODX) In Focus After Its Latest Molecular Diagnostics Update?
July 31, 2026  |  kalkinemedia.comK
Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
July 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-announces-second-quarter-2026-earnings-release-date-and-webcast-302838779.html
Exclusive: Co-Diagnostics announces successful proof of concept for extraction-free Ebola test
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/science/microbiology/exclusive-co-diagnostics-announces-successful-proof-of-concept-for-extraction-free-ebola-test/ar-AA28ROID
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-provides-ebola-test-kits-for-analytical-studies-302836033.html
Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-initiates-clinical-studies-in-india-for-tuberculosis-test-on-pcr-platform-302831652.html
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
July 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-appoints-wes-lindsey-phd-mba-as-chief-scientific-officer-302827367.html
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-invited-to-participate-in-npoc-tuberculosis-diagnostics-workshop-in-bangkok-thailand-302820333.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$1.10 -0.02 (-1.34%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas